JonesResearch lowered the firm’s price target on Theratechnologies to $5 from $9 and keeps a Buy rating on the shares. The company’s public offering last week of 12.5M shares eases near-term concerns over liquidity and on-going concern considerations that have weighed on the stock, the analyst tells investors in a research note. However, the price of the offering was lower than estimated and, consequently, more dilutive to shareholders, says the firm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on THTX:
- Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
- Theratechnologies 12.5M share Spot Secondary priced at $1.00
- Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
- Theratechnologies announces common stock offering, private placement
- Theratechnologies announces operational update
